JW (Cayman) Therapeutics Co. Ltd
JWCTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $106 | $71 | $87 | $86 |
| % Growth | 48.9% | -17.8% | 0.8% | – |
| Cost of Goods Sold | $41 | $38 | $43 | $43 |
| Gross Profit | $65 | $34 | $44 | $43 |
| % Margin | 61.2% | 47% | 50.4% | 50.4% |
| R&D Expenses | $92 | $132 | $151 | $197 |
| G&A Expenses | $32 | $61 | $59 | $61 |
| SG&A Expenses | $91 | $125 | $135 | $114 |
| Sales & Mktg Exp. | $58 | $64 | $76 | $53 |
| Other Operating Expenses | $0 | -$471 | $5 | $132 |
| Operating Expenses | $183 | -$214 | $291 | $443 |
| Operating Income | -$118 | $248 | -$248 | -$400 |
| % Margin | -110.6% | 346.6% | -285.1% | -464.1% |
| Other Income/Exp. Net | -$150 | -$598 | $7 | $12 |
| Pre-Tax Income | -$267 | -$350 | -$240 | -$388 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$267 | -$350 | -$240 | -$388 |
| % Margin | -251.3% | -490.7% | -276.8% | -450.1% |
| EPS | -0.64 | -0.84 | -0.58 | -0.94 |
| % Growth | 23.8% | -44.8% | 38.3% | – |
| EPS Diluted | -0.64 | -0.84 | -0.58 | -0.94 |
| Weighted Avg Shares Out | 416 | 414 | 413 | 412 |
| Weighted Avg Shares Out Dil | 416 | 414 | 413 | 412 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $9 | $0 | $12 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $34 | $32 | $36 | $36 |
| EBITDA | -$80 | -$186 | -$205 | -$225 |
| % Margin | -75.3% | -260.7% | -236% | -261.8% |